907 Results for "

Inactive

" in MedChemExpress (MCE) Product Catalog:
Products (907)

907 Results for "Inactive" in MCE Product Catalog:

Cat. No.: HY-13551C
CAS No.: 80277-14-1
Synonyms: m-AMSA isethionate; Acridinyl anisidide isethionate
Amsacrine isethionate (m-AMSA isethionate) is a Topoisomerase II inhibitor. Amsacrine isethionate intercalates into DNA. Amsacrine isethionate induces Ca 2+-mediated inactivation of ERK, and also downregulates AKT, promoting MCL1 downregulation mediated by GSK3β via reducing the phosphorylation level of GSK3β. Amsacrine isethionate induces Apoptosis by activating Caspase-9 and Caspase-3. Amsacrine isethionate blocks HERG potassium channels in the open/inactivated state. Amsacrine isethionate induces chromosomal aberrations and sister chromatid exchanges, and inhibits the synthesis of RNA and DNA. Amsacrine isethionate exhibits anti-leukemic activity. Amsacrine isethionate causes cardiac repolarization disorders, QT interval prolongation, ventricular arrhythmias, and increases the risk of sudden cardiac death. Amsacrine isethionate can be used in research related to acute myeloid leukemia, lymphoma and progressive malignancies .
loading...
    loading...
Cat. No.: HY-13551D
CAS No.: 80277-11-8
Synonyms: m-AMSA lactate; Acridinyl anisidide lactate
Amsacrine lactate (m-AMSA lactate) is a Topoisomerase II inhibitor. Amsacrine lactate intercalates into DNA. Amsacrine lactate induces Ca 2+-mediated inactivation of ERK, and also downregulates AKT, promoting MCL1 downregulation mediated by GSK3β via reducing the phosphorylation level of GSK3β. Amsacrine lactate induces Apoptosis by activating Caspase-9 and Caspase-3. Amsacrine lactate blocks HERG potassium channels in the open/inactivated state. Amsacrine lactate induces chromosomal aberrations and sister chromatid exchanges, and inhibits the synthesis of RNA and DNA. Amsacrine lactate exhibits anti-leukemic activity. Amsacrine lactate causes cardiac repolarization disorders, QT interval prolongation, ventricular arrhythmias, and increases the risk of sudden cardiac death. Amsacrine lactate can be used in research related to acute myeloid leukemia, lymphoma and progressive malignancies .
loading...
    loading...
Cat. No.: HY-176785S
MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with Kds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC50s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRAS G12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer .
loading...
    loading...
Cat. No.: HY-181964
CAS No.: 3023465-19-9
Research Areas:  

Cancer

KRAS G12C-IN-77 is an orally active and selective KRAS G12C covalent dual-state inhibitor that binds with high affinity to both GDP-bound (inactive state) and GTP-bound (active state) KRAS G12C (IC50 = 133 nM). KRAS G12C-IN-77 rapidly inhibits ERK1/2 phosphorylation, induces the formation of covalent adducts with endogenous KRAS G12C, suppresses the expression of MAPK pathway genes, and inhibits the proliferation of KRAS G12C-mutant cells. KRAS G12C-IN-77 is applicable to research related to KRAS G12C-mutant solid tumors, including pancreatic ductal adenocarcinoma and non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-Y0070
CAS No.: 420-04-2
Cyanamide is a cell division and plant growth inhibitor, as well as an allelochemical derived from Vicia villosa. Cyanamide inhibits root growth and biomass accumulation in a dose-dependent manner by disrupting the formation of mitotic spindles and phragmoplast complexes, reducing the number of mitotic cells and blocking the cell cycle. The effects of Cyanamide are partially reversible after removal from low-concentration environments. Cyanamide is also a specific inhibitor of aldehyde dehydrogenase (ALDH). Although Cyanamide has no direct effect on tumor growth, it can significantly enhance the anti-tumor efficacy of Cyclophosphamide (HY-17420) at non-toxic doses by inhibiting the inactivation of Cyclophosphamide. Cyanamide enables Cyclophosphamide to exert equivalent therapeutic effects at lower doses, effectively inhibiting the growth of primary and metastatic tumors and prolonging the lifespan of tumor-bearing mice. Cyanamide is commonly used in studies related to ha-1 hepatoma and rls lymphosarcoma .
loading...
    loading...
Cat. No.: HY-L024
931 compounds

A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.

MCE owns a unique collection of 931 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

Cat. No.: HY-D1005I
CAS No.: 9003-11-6
Poloxamer L61 is a non-ionic triblock copolymer surfactant. Poloxamer L61 effectively achieves intracellular molecular delivery to cancer cells during photoacoustic molecular delivery, and maintains cell viability by promoting cell membrane resealing, thus avoiding irreversible damage caused by laser-induced membrane permeabilization. Poloxamer L61 is a key component of SP1017, a compound related to gene therapy, which regulates the interaction between DNA and extracellular matrix as well as cellular uptake, and significantly enhances the distribution and bioavailability of plasmid DNA in skeletal muscle. Poloxamer L61 can be used in studies on local or systemic therapeutic protein production .
loading...
    loading...
Cat. No.: HY-P73825
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: MAP2K1; MAPKK1; Prev. PRKMK1; MAPKK 1; Dual Specificity Mitogen-Activated Protein Kinase Kinase 1; MEK 1; MAPK/ERK Kinase 1; Protein Kinase, Mitogen-Activated, Kinase 1 (MAP Kinase Kinase 1); MEK1; CFC3; MKK1; MEL; ERK Activator Kinase 1; Mitogen-Activate
Species:  
Mouse
Source:  
Sf9 insect cells
loading...
    loading...
Cat. No.: HY-P75668
Purity:  ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: CDK1; Cell Division Protein Kinase 1; Prev. CDC2; P34 Protein Kinase; CDC28A; P34CDC2; Cell Division Cycle 2, G1 To S And G2 To M; Cell Cycle Controller CDC2; Cell Division Control Protein 2 Homolog; CDKN1; Cyclin Dependent Kinase 1; Cyclin-Dependent Kina
Species:  
Human
Source:  
Sf9 insect cells
loading...
    loading...
Cat. No.: HY-P703586
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: MAP2K1; MAPKK1; Prev. PRKMK1; MAPKK 1; Dual Specificity Mitogen-Activated Protein Kinase Kinase 1; MEK 1; MAPK/ERK Kinase 1; Protein Kinase, Mitogen-Activated, Kinase 1 (MAP Kinase Kinase 1); MEK1; CFC3; MKK1; MEL; ERK Activator Kinase 1; Mitogen-Activate
Species:  
Human
Source:  
Sf9 insect cells
loading...
    loading...
Cat. No.: HY-P705725
Purity:  ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: ABL1; BCR/ABL1 E1a2 Fusion Protein; Prev. ABL; Bcr/C-Abl Oncogene Protein; JTK7; Chimeric BCR::ABL1 Protein; P150; BCR::ABL1 Fusion Protein; C-ABL; BCR/ABL E8a2 Fusion; V-Abl Abelson Murine Leukemia Viral Oncogene Homolog 1; BCR/ABL1 Fusion; C-Abl Oncogen
Species:  
Human
Source:  
sf9 insect cells
loading...
    loading...
Cat. No.: HY-151886
CAS No.: 2759420-43-2
NU223612 is a cereblon (CRBN)-recruiting IDO1 PROTAC degrader, with a DC50 value of 0.329-0.5438 μM against human IDO1, and it is capable of penetrating the blood-brain barrier. NU223612 directly binds to IDO1, mediates the degradation of both wild-type and catalytically inactive mutant IDO1 proteins, and does not degrade TDO2. NU223612 inhibits IDO1-mediated enzymatic activity. NU223612 directly binds to CRBN and promotes the formation of a cooperative ternary complex with IDO1. NU223612 induces ubiquitin-dependent proteasomal degradation of the IDO1 protein. NU223612 suppresses IDO1-mediated non-enzymatic phosphorylation of NF-κB p65 and the DNA-binding activity of downstream transcription factors. NU223612 can be used in studies of glioblastoma (malignant glioma) .
loading...
    loading...
Cat. No.: HY-183335
Research Areas:  

Cancer

Anticancer agent 321 is a Smoothened (SMO) inhibitor with a human IC50 of 0.12 μM, enhanced aqueous solubility, good plasma and metabolic stability, moderate therapeutic index, preliminary safety profile, and moderate oral bioavailability in rats.Anticancer agent 321 binds to SMO’s 7-transmembrane helical channel, forming hydrogen bonds with Asp384 and hydrophobic/π-π interactions with His470, Phe391, Tyr394, stabilizing SMO’s inactive conformation to inhibit Hedgehog/GLI signaling.Anticancer agent 321 inhibits proliferation, suppresses colony formation, induces apoptosis, and downregulates Hedgehog/GLI pathway target genes GLI1, GLI2, Ptch1, HHip in cancer cells.Anticancer agent 321 inhibits tumor growth, downregulates Ki67 and SOX2, and upregulates cleaved-caspase 3 in tumor tissues.Anticancer agent 321 can be used for the research of cutaneous squamous cell carcinoma .
loading...
    loading...
Cat. No.: HY-P10984
CAS No.: 206536-96-1
FNIII14 is a β1-integrin inhibitory peptide. FNIII14 induces the conformational shift of β1-integrin from the active form to the inactive form, blocks integrin-mediated signaling pathways, disrupts the interaction between VLA-4 and fibronectin, inhibits the phosphorylation of FAK/Akt, suppresses cell adhesion, fibronectin fibril formation and chondrocyte proliferation, induces chondrocyte apoptosis and cartilage degeneration, upregulates the pro-apoptotic protein Bim, and binds to membrane-bound eEF1A. FNIII14 reversibly disrupts cell adhesion without reducing cell viability, accelerates adipocyte differentiation, and loosens tumor matrix architecture to enhance the permeability of nanotherapeutic agents. FNIII14 can be used in research related to neuroblastoma, pancreatic cancer, acute myeloid leukemia, colitis-associated colorectal cancer, osteoarthritis, and atherosclerosis .
loading...
    loading...
Cat. No.: HY-P2114
CAS No.: 173959-12-1
Target:  

Inhibitory Antibodies

Research Areas:  

Cancer

IT9302 is a synthetic IL-10 agonist with the activity of inducing tolerogenic dendritic cells. IT9302 is able to mimic multiple effects of IL-10, including downregulating the antigen presentation machinery and increasing the sensitivity of tumor cells to natural killer cell-mediated lysis. IT9302 can also hinder the response of human monocytes to differentiation factors and reduce the antigen presentation and co-stimulatory capacity of dendritic cells. Dendritic cells treated with IT9302 showed a weakened ability to stimulate T cell proliferation and interferon-γ production. IT9302 exerts its effects through mechanisms that are partially different from IL-10, involving STAT3 inactivation and regulation of the NF-κB intracellular pathway. IT9302-treated dendritic cells showed enhanced expression of membrane-bound TGF-β, associated with the effective induction of foxp3+ regulatory T cells .
loading...
    loading...
Cat. No.: HY-169798
CAS No.: 23481-50-7
Target:  

Fluorescent Dye VSV

Research Areas:  

Infection

1,9-Dimethylmethylene blue is a photosensitizer, virus inactivator and hemoglobin oxidant derived from methylene blue. When activated, 1,9-Dimethylmethylene blue generates reactive oxygen species including singlet oxygen, and acts as a metachromatic dye. When activated in monomeric or dimeric form, 1,9-Dimethylmethylene blue induces photoinactivation of R17 phage and vesicular stomatitis virus and oxidizes hemoglobin via non-singlet oxygen reactive oxygen species or singlet oxygen-mediated pathways, respectively. The monomeric form, with higher nucleic acid affinity, achieves virus inactivation under specific conditions without forming methemoglobin. 1,9-Dimethylmethylene blue binds to substances such as glycosaminoglycans to produce color changes. Although it is susceptible to interference from non-glycosaminoglycan components in urine, it is still applicable to spectrophotometric analysis for glycosaminoglycan quantification. With these unique photochemical and binding properties, 1,9-Dimethylmethylene blue is widely used in studies of viral infections and related biochemical analyses .
loading...
    loading...
Cat. No.: HY-W720629
CAS No.: 21420-37-1
Cyanamide- 15N2 is the 15N-labeled Cyanamide (HY-Y0070). Cyanamide is a cell division and plant growth inhibitor, as well as an allelochemical derived from Vicia villosa. Cyanamide inhibits root growth and biomass accumulation in a dose-dependent manner by disrupting the formation of mitotic spindles and phragmoplast complexes, reducing the number of mitotic cells and blocking the cell cycle. The effects of Cyanamide are partially reversible after removal from low-concentration environments. Cyanamide is also a specific inhibitor of aldehyde dehydrogenase (ALDH). Although Cyanamide has no direct effect on tumor growth, it can significantly enhance the anti-tumor efficacy of Cyclophosphamide (HY-17420) at non-toxic doses by inhibiting the inactivation of Cyclophosphamide. Cyanamide enables Cyclophosphamide to exert equivalent therapeutic effects at lower doses, effectively inhibiting the growth of primary and metastatic tumors and prolonging the lifespan of tumor-bearing mice. Cyanamide is commonly used in studies related to ha-1 hepatoma and rls lymphosarcoma .
loading...
    loading...
Cat. No.: HY-P706075
Purity:  ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: MAP2K1; MAPKK1; Prev. PRKMK1; MAPKK 1; Dual Specificity Mitogen-Activated Protein Kinase Kinase 1; MEK 1; MAPK/ERK Kinase 1; Protein Kinase, Mitogen-Activated, Kinase 1 (MAP Kinase Kinase 1); MEK1; CFC3; MKK1; MEL; ERK Activator Kinase 1; Mitogen-Activated Protein Kinase Kinase 1; MAP Kinase Kinase 1
Species:  
Human
Source:  
Sf9 insect cells
loading...
    loading...
Cat. No.: HY-P76588
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: RPS6KB1; Ribosomal Protein S6 Kinase, 70kDa, Polypeptide 1; Prev. STK14A; 70 KDa Ribosomal Protein S6 Kinase 1; S6K1; Serine/Threonine Kinase 14 Alpha; P70(S6K)-Alpha; P70 Ribosomal S6 Kinase Alpha; PS6K; P70 S6 Kinase Alpha; S6K; RPS6KB1 Protein; Serine/
Species:  
Human
Source:  
Sf9 insect cells
loading...
    loading...
Cat. No.: HY-P703590
Purity:  ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: RPS6KB2; S6K-Beta; Ribosomal Protein S6 Kinase B2; P70 S6KB; STK14B; P70S6K2; P70-BETA; S6K2; P70S6Kb; SRK; S6Kbeta; Ribosomal Protein S6 Kinase, 70kDa, Polypeptide 2; S6KB; Ribosomal Protein S6 Kinase, 70kD, Polypeptide 2; KLS; Serine/Threonine-Protein K
Species:  
Human
Source:  
Sf9 insect cells
loading...
    loading...